NEW YORK (GenomeWeb News) – Atossa Genetics reported after the close of the market on Thursday $105,576 in revenues for the third quarter compared to no revenues in the year-ago period.

For the three months ended Sept. 30, revenues were comprised of $104,011 in Diagnostic Testing Services and $1,565 in product sales. The Seattle-based firm launched ForeCYTE and ArgusCYTE tests a year ago and said today that it expects to roll out the tests nationally in early 2013.

Atossa said that its SG&A spending retreated 3 percent to $1.23 million from $1.27 million a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.